National Eczema Association’s Post

Treatment options continue to expand for our community! Today the FDA approved Zoryve cream (roflumilast 0.15%), from manufacturer Arcutis Biotherapeutics, for the treatment of mild to moderate atopic dermatitis in adults and children ages 6 and older. Zoryve is available by prescription only. Learn more: https://lnkd.in/gDJTCrbV #EczemaTreatment #EczemaCare #EczemaRelief #EczemaMedications #EczemaTherapies #EczemaManagement #EczemaTopicals #TopicalTreatment #NewTreatment #NovelTherapy

Breaking News: FDA Approves Zoryve Cream (Roflumilast 0.15%) for Atopic Dermatitis -- Zoryve Foam 0.3% was Previously Approved for Seborrheic Dermatitis

Breaking News: FDA Approves Zoryve Cream (Roflumilast 0.15%) for Atopic Dermatitis -- Zoryve Foam 0.3% was Previously Approved for Seborrheic Dermatitis

google.com

To view or add a comment, sign in

Explore topics